Log in to save to my catalogue

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-T...

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-T...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837069

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study

Publication information

Publisher

Switzerland: MDPI AG

More information

Scope and Contents

Contents

We evaluated the 3-year drug survival and efficacy of the biosimilar SB4/Benepali in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients, previously treated with etanercept (ETA). Drug survival rate was calculated using the Kaplan–Meier method and Cox proportional hazard models were developed to examine pre...

Alternative Titles

Full title

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837069

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8837069

Other Identifiers

ISSN

2077-0383

E-ISSN

2077-0383

DOI

10.3390/jcm11030621

How to access this item